Pediatric AML: From Biology to Clinical Management.

Pediatric AML: From Biology to Clinical Management.
复制标题

DOI:
10.3390/jcm4010127
复制
发表时间:
2015-01-09
影响因子:
3.9
通讯作者:
van den Heuvel-Eibrink M
van den Heuvel-Eibrink M
中科院分区:
医学2区
文献类型:
--
作者:
de Rooij JD;Zwaan CM;van den Heuvel-Eibrink M

文献摘要

参考文献

被引文献

相似文献

Pediatric acute myeloid leukemia (AML) represents 15%–20% of all pediatric acute leukemias. Survival rates have increased over the past few decades to ~70%, due to improved supportive care, optimized risk stratification and intensified chemotherapy. In most children, AML presents as a de novo entity, but in a minority, it is a secondary malignancy. The diagnostic classification of pediatric AML includes a combination of morphology, cytochemistry, immunophenotyping and molecular genetics. Outcome is mainly dependent on the initial response to treatment and molecular and cytogenetic aberrations. Treatment consists of a combination of intensive anthracycline- and cytarabine-containing chemotherapy and stem cell transplantation in selected genetic high-risk cases or slow responders. In general, ~30% of all pediatric AML patients will suffer from relapse, whereas 5%–10% of the patients will die due to disease complications or the side-effects of the treatment. Targeted therapy may enhance anti-leukemic efficacy and minimize treatment-related morbidity and mortality, but requires detailed knowledge of the genetic abnormalities and aberrant pathways involved in leukemogenesis. These efforts towards future personalized therapy in a rare disease, such as pediatric AML, require intensive international collaboration in order to enhance the survival rates of pediatric AML, while aiming to reduce long-term toxicity.
DOI: 10.3324/haematol.2014.104182
发表时间: 2014-09-01
期刊: HAEMATOLOGICA
影响因子: 10.1
作者:
Creutzig, Ursula;Zimmermann, Martin;Kaspers, Gertjan L.
通讯作者: Kaspers, Gertjan L.
DOI: 10.1038/sj.leu.2404605
发表时间: 2007-05-01
期刊: LEUKEMIA
影响因子: 11.4
作者:
Debernardi, S.;Skoulakis, S.;Young, B. D.
通讯作者: Young, B. D.
DOI: 10.1002/cncr.28674
发表时间: 2014-08-15
期刊: CANCER
影响因子: 6.2
作者:
Cooper, Todd M.;Alonzo, Todd A.;Gerbing, Robert B.;Perentesis, John P.;Whitlock, James A.;Taub, Jeffrey W.;Horton, Terzah M.;Gamis, Alan S.;Meshinchi, Soheil;Loken, Michael R.;Razzouk, Bassem I.
通讯作者: Razzouk, Bassem I.
DOI: 10.1038/leu.2010.47
发表时间: 2010-05-01
期刊: LEUKEMIA
影响因子: 11.4
作者:
Balgobind, B. V.;Lugthart, S.;van den Heuvel-Eibrink, M. M.
通讯作者: van den Heuvel-Eibrink, M. M.
DOI: 10.7326/0003-4819-103-3-460
发表时间: 1985-01-01
影响因子: 39.2
作者:
BENNETT, JM;CATOVSKY, D;SULTAN, C
通讯作者: SULTAN, C